3/20
08:05 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
3/20
08:05 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $46.00 price target on the stock.
3/20
06:51 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
3/20
06:51 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
3/20
03:51 am
cldx
Celldex initiated with an Overweight at Morgan Stanley
Low
Report
Celldex initiated with an Overweight at Morgan Stanley
3/20
03:51 am
cldx
Celldex initiated with an Overweight at Morgan Stanley
Low
Report
Celldex initiated with an Overweight at Morgan Stanley
3/3
09:44 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
3/3
09:44 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
3/3
09:44 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX
2/28
08:13 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
2/13
09:16 am
cldx
Rating for CLDX
Low
Report
Rating for CLDX
2/13
08:08 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $44.00 price target on the stock.
Low
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $44.00 price target on the stock.
2/13
07:52 am
cldx
Celldex initiated with a Buy at UBS
Medium
Report
Celldex initiated with a Buy at UBS
1/29
09:59 am
cldx
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Medium
Report
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
1/29
09:45 am
cldx
Rating for CLDX
Medium
Report
Rating for CLDX